Literature DB >> 17187877

Total ghrelin plasma level in patients with the restrictive type of anorexia nervosa.

Malgorzata Janas-Kozik1, Irena Krupka-Matuszczyk, Izabela Malinowska-Kolodziej, Joanna Lewin-Kowalik.   

Abstract

Ghrelin is produced mainly in the stomach and is an essential link of the brain-gut axis. Ghrelin stimulates hunger centers in hypothalamus controlling food intake and body mass gain. The aim of the study is to analyze the total ghrelin plasma level in patients suffering from restrictive type of anorexia nervosa (AN-R). According to DSM-IV classification a group of 30 AN-R patients was investigated before and after 3 and 6 months of therapy. Therapy included normocaloric diet and cognitive-behavioral psychotherapy (CBT). The control group consisted of 20 girls without any eating disorders. Before the therapy the total ghrelin plasma level in AN-R patients was significantly higher than in the control group. After 3 and 6 months of treatment the total ghrelin plasma level in AN-R patients was significantly lower than in the control group. In AN-R patients, the total ghrelin plasma level is connected with the pathological feeding behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17187877     DOI: 10.1016/j.regpep.2006.11.005

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  15 in total

1.  Abnormal relationships between the neural response to high- and low-calorie foods and endogenous acylated ghrelin in women with active and weight-recovered anorexia nervosa.

Authors:  Laura M Holsen; Elizabeth A Lawson; Kara Christensen; Anne Klibanski; Jill M Goldstein
Journal:  Psychiatry Res       Date:  2014-05-06       Impact factor: 3.222

Review 2.  Anorexia Nervosa and Its Associated Endocrinopathy in Young People.

Authors:  Madhusmita Misra; Anne Klibanski
Journal:  Horm Res Paediatr       Date:  2016-02-11       Impact factor: 2.852

Review 3.  Role of ghrelin in the pathophysiology of eating disorders: implications for pharmacotherapy.

Authors:  Sebastian Cardona Cano; Myrte Merkestein; Karolina P Skibicka; Suzanne L Dickson; Roger A H Adan
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

4.  Factors associated with fasting plasma ghrelin levels in children and adolescents.

Authors:  Chao-Chun Zou; Li Liang; Zheng-Yan Zhao
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

Review 5.  Obesity vaccines.

Authors:  Mariana P Monteiro
Journal:  Hum Vaccin Immunother       Date:  2013-12-23       Impact factor: 3.452

Review 6.  Ghrelin and eating disorders.

Authors:  Deniz Atalayer; Charlisa Gibson; Alexandra Konopacka; Allan Geliebter
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-08-30       Impact factor: 5.067

7.  Ghrelin and NUCB2/nesfatin-1 are expressed in the same gastric cell and differentially correlated with body mass index in obese subjects.

Authors:  Andreas Stengel; Tobias Hofmann; Miriam Goebel-Stengel; Vanessa Lembke; Anne Ahnis; Ulf Elbelt; Nils W G Lambrecht; Jürgen Ordemann; Burghard F Klapp; Peter Kobelt
Journal:  Histochem Cell Biol       Date:  2013-03-21       Impact factor: 4.304

Review 8.  The role of ghrelin, salivary secretions, and dental care in eating disorders.

Authors:  Takakazu Yagi; Hirotaka Ueda; Haruka Amitani; Akihiro Asakawa; Shouichi Miyawaki; Akio Inui
Journal:  Nutrients       Date:  2012-08-13       Impact factor: 5.717

9.  Comparison of a high-carbohydrate and high-protein breakfast effect on plasma ghrelin, obestatin, NPY and PYY levels in women with anorexia and bulimia nervosa.

Authors:  Dana Sedlackova; Jana Kopeckova; Hana Papezova; Vojtech Hainer; Hana Kvasnickova; Martin Hill; Jara Nedvidkova
Journal:  Nutr Metab (Lond)       Date:  2012-06-08       Impact factor: 4.169

10.  Ghrelin: central and peripheral implications in anorexia nervosa.

Authors:  Mathieu Méquinion; Fanny Langlet; Sara Zgheib; Suzanne Dickson; Bénédicte Dehouck; Christophe Chauveau; Odile Viltart
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-26       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.